The Technical Analyst
Vaccinex Inc [VCNX]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Vaccinex Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
3.40% $4.86
America/New_York / 19 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 6.92 mill |
| EPS: | -43.68 |
| P/E: | -0.110 |
| Earnings Date: | May 13, 2024 |
| SharesOutstanding: | 1.425 mill |
| Avg Daily Volume: | 0.0133 mill |
| RATING 2024-04-19 |
|---|
| C+ |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Sell | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Sell | |
| P/E: | Neutral | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | |||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.110 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.02x |
| Company: PE -0.110 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 4.18 - 5.54 ( +/- 13.91%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-28 | Zauderer Maurice | Buy | 38 610 | Common Stock |
| 2024-03-28 | Zauderer Maurice | Buy | 38 610 | Warrant (Right to Buy) |
| 2024-03-28 | Friedberg Albert | Buy | 102 960 | Common Stock |
| 2024-03-28 | Friedberg Albert | Buy | 102 960 | Warrant (Right to Buy) |
| 2024-03-20 | Evans Elizabeth E. | Buy | 1 341 | Stock Option (Right to Buy) |
| INSIDER POWER |
|---|
| 99.87 |
| Last 100 transactions |
| Buy: 40 295 196 | Sell: 9 809 782 |
Forecast:
16:00 - $4.99
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $4.99
Forecast 2: 16:00 - $4.99
Forecast 3: 16:00 - $4.99
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $4.86 (3.40% ) |
| Volume | 0.0079 mill |
| Avg. Vol. | 0.0133 mill |
| % of Avg. Vol | 59.22 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For VCNX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
VCNX
Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs. The company offers its products for the treatment of cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab, a humanized monoclonal antibody that completed and planned Phase 1b/2 clinical trials for the treatment of non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), Huntington's disease, Alzheimer's disease, osteosarcoma, and melanoma. The company is also developing VX5, a human antibody to CXCL13 that is in preclinical development for the treatment of MS and for other autoimmune disorders. Vaccinex, Inc. was incorporated in 2001 and is headquartered in Rochester, New York.
Last 10 Buy Signals
Latest Press Releases
2024-04-02 08:30:00 - Press Release
Vaccinex Reports 2023 Financial Results And Provides Corporate Update
Expect topline data for randomized signal-ad study of pepinemab for alzheimer's disease in q3 2024. $17.9 million of new financing in q4 2023 and q1 2024.
2024-03-27 08:30:00 - Press Release
Vaccinex, Inc. Announces $1.5 Million Registered Direct Offering And Concurrent Private Placement Priced At-the-market Under Nasdaq Rules
Rochester, n.y., march 27, 2024 (globe newswire) -- vaccinex, inc. (nasdaq: vcnx) (“vaccinex” or the “company”), a clinical-stage biotechnology company pioneering a differentiated approach to treating alzheimer's disease and cancer through the inhibition of sema4d, today announced that it has entered into definitive agreements with certain institutional investors for the purchase and sale of 193,000 shares of its common stock in a registered direct offering together with warrants to purchase up to an aggregate of 193,000 shares of common stock in a concurrent private placement priced at-the-market under nasdaq rules at a combined purchase price of $7.77 per share and accompanying warrant...
2024-02-21 08:00:00 - Press Release
Vaccinex Announces Multiple New Agreements For Access To Activmab® Antigen Virus Technology
Eight new antibody discovery agreements incorporate vaccinex's powerful activmab® drug discovery platform activmab® platform enables the discovery and development of high value antibodies against challenging multi-pass membrane targets rochester, n.y., feb. 21, 2024 (globe newswire) -- vaccinex, inc. (nasdaq: vcnx), a clinical-stage biotechnology company pioneering a differentiated approach to treating alzheimer's disease and cancer through the inhibition of sema4d, announces that it has entered into eight new antibody discovery agreements integrating use of its proprietary activmab platform to select antibodies against difficult-to-drug transmembrane protein targets.
2024-02-15 08:00:00 - Press Release
Vaccinex, Inc. Announces Reverse Stock Split
Rochester, n.y., feb. 15, 2024 (globe newswire) -- vaccinex, inc., (nasdaq: vcnx), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the inhibition of sema4d, today announced that it will effect a 1-for-14 reverse stock split of its issued common stock, effective at 5:00 p.m. eastern time on monday, february 19, 2024. beginning tuesday, february 20, 2024, the company's common stock will trade on a split-adjusted basis.
2024-02-07 08:00:00 - Press Release
Vaccinex Announces Pricing Of $3.7 Million Pipe Financing
Rochester, n.y., feb. 07, 2024 (globe newswire) -- vaccinex, inc. (nasdaq: vcnx) (“vaccinex” or the “company”), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease by blocking astrogliosis and neuroinflammation through the inhibition of sema4d, today announced it has priced a $3.7 million private placement transaction with a lead investment from a major new investor alongside significant participation from existing investors, including entities affiliated with the chairman of the company's board of directors and the company's chief executive officer. the securities purchase agreement for the financing provides for the sale of an aggregate of 3,838,544 shares of the company's common stock (and 1,265,078 common stock equivalents in lieu of common stock) together with common warrants to purchase up to an equal number (5,103,622) of shares of common stock...
Latest News
2023-10-26 11:00:20 - PennyStocks
Best Penny Stocks To Buy Now? 4 Biotech Stocks To Watch
If you're wondering what is going on in the stock market today or which penny stocks to buy now that major indexes are lower, you're not alone. Earnings season mixed with economic data has resulted in a sharp downturn for the market.
2023-10-06 08:08:14 - InvestorPlace
Why Is Vaccinex (VCNX) Stock Up 26% Today?
Vaccinex (NASDAQ: VCNX ) stock is climbing higher on Friday after the clinical-stage biotechnology company announced insider buying. These insider trading actions were revealed by Vaccinex in a series of filings with the Securities and Exchange Commission (SEC).
2023-04-06 22:23:16 - 24/7 Wall Street
Fcmi Parent Now Owns 42.8% of Vaccinex
Fintel reports that Fcmi Parent has filed a 13D/A form with the SEC disclosing ownership of 23.49MM shares of Vaccinex Inc (VCNX).
2023-03-23 08:00:00 - GlobeNewsWire
Vaccinex, Inc. to Present at the 2023 AAIC Advancements: Immunity Conference
March 24th presentation to highlight learnings related to pepinemab's mechanism of action in both Huntington's Disease and Alzheimer's Disease March 24th presentation to highlight learnings related to pepinemab's mechanism of action in both Huntington's Disease and Alzheimer's Disease
2023-02-07 11:10:11 - MarketBeat
Should Investors Buy or Sell the Vaccinex Patent News?
Shares of Vaccinex, Inc. (NASDAQ: VCNX) are charging higher on February 7 on news that the clinical-stage biotechnology company secured a patent. VCNX stock increased by more than 20% in pre-market trading on the news.
2023-02-07 09:12:37 - PennyStocks
7 Penny Stocks To Watch With Big News In February; Time To Buy?
Penny stocks to watch with news this month. The post 7 Penny Stocks To Watch With Big News In February; Time To Buy?
2023-02-07 07:41:52 - InvestorPlace
Why Is Vaccinex (VCNX) Stock Up 67% Today?
Vaccinex (NASDAQ: VCNX ) stock is rocketing higher on Tuesday despite a lack of news from the clinical-stage biotechnology company. Instead, it looks like today's gains come from increased interest from investors.
2023-01-26 18:06:46 - InvestorPlace
The 3 Best Biotech Stocks Under $1 to Buy for January
While biotech may be the next big thing, making money through it isn't easy. Indeed, investing in biotech stocks is often more of an art than a science.
2022-02-24 08:00:00 - GlobeNewsWire
Vaccinex, Inc. to Present at CHDI's 17th Annual HD Therapeutics Conference Meeting
Poster Presentation: Combination immunotherapy and HTT-lowering in humanized HD mice, Wednesday, March 2, 2022 Poster Presentation: Combination immunotherapy and HTT-lowering in humanized HD mice, Wednesday, March 2, 2022
2022-02-08 14:41:04 - PennyStocks
8 Penny Stocks To Buy Now According To Insiders In 2022
Penny stocks to buy now according to insiders. The post 8 Penny Stocks To Buy Now According To Insiders In 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.